Perbak Capital Partners LLP Grows Stake in ICU Medical, Inc. $ICUI

Perbak Capital Partners LLP lifted its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 139.3% in the third quarter, Holdings Channel.com reports. The firm owned 11,246 shares of the medical instruments supplier’s stock after buying an additional 6,547 shares during the period. Perbak Capital Partners LLP’s holdings in ICU Medical were worth $1,349,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. River Road Asset Management LLC raised its stake in shares of ICU Medical by 207.0% in the second quarter. River Road Asset Management LLC now owns 651,492 shares of the medical instruments supplier’s stock valued at $83,658,000 after acquiring an additional 439,263 shares during the period. Norges Bank purchased a new position in shares of ICU Medical during the 2nd quarter worth about $36,633,000. UBS Group AG grew its holdings in ICU Medical by 239.8% during the 3rd quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier’s stock valued at $46,371,000 after purchasing an additional 272,782 shares during the last quarter. Schroder Investment Management Group grew its holdings in ICU Medical by 25.2% during the 3rd quarter. Schroder Investment Management Group now owns 796,704 shares of the medical instruments supplier’s stock valued at $93,246,000 after purchasing an additional 160,380 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in ICU Medical by 16.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 872,993 shares of the medical instruments supplier’s stock worth $104,718,000 after purchasing an additional 126,072 shares during the period. Institutional investors own 96.10% of the company’s stock.

ICU Medical Trading Down 2.3%

Shares of NASDAQ:ICUI opened at $125.85 on Friday. The company has a market capitalization of $3.11 billion, a PE ratio of 6,295.65, a P/E/G ratio of 1.86 and a beta of 0.79. The company has a current ratio of 2.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.60. ICU Medical, Inc. has a 12-month low of $107.00 and a 12-month high of $160.29. The business’s fifty day simple moving average is $147.98 and its 200-day simple moving average is $138.00.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.68 by $0.23. ICU Medical had a net margin of 0.03% and a return on equity of 7.33%. The firm had revenue of $535.94 million for the quarter, compared to the consensus estimate of $541.20 million. During the same quarter in the previous year, the firm earned $2.11 EPS. The company’s quarterly revenue was down 14.1% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, equities research analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ICUI shares. Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Sunday, February 15th. Piper Sandler upped their price objective on ICU Medical from $172.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, February 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a research report on Thursday, January 22nd. Finally, KeyCorp boosted their target price on shares of ICU Medical from $175.00 to $180.00 and gave the company an “overweight” rating in a research note on Friday, February 20th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, ICU Medical currently has an average rating of “Moderate Buy” and a consensus target price of $179.33.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.